Learning
19-20 December 2025 | India, Gurugram
ILCA School of Liver Cancer
The ILCA School of Liver Cancer 2025 was supported by an unrestricted educational grant from AstraZeneca
Learning
Key Learnings from ILCA School 2025
Overall, the School successfully delivered high-impact, practice-oriented education, blending international expertise with Indian clinical perspectives, and fostered meaningful academic exchange among hepatologists, oncologists, surgeons, interventional radiologists, and trainees.
Indian ground realities: Rising burden of HCC and CCA, MASLD-driven HCC, viral hepatitis–related oncogenesis, and challenges in surveillance penetration.
Biology to bedside: Tumor microenvironment, molecular sub-typing of CCA, liquid biopsy, and translational biomarkers.
Detection & staging: LI-RADS utility, AMRI and biomarker panels, and practical staging algorithms for routine clinical use.
Curative and locoregional approaches: Resection eligibility, transplant criteria, downstaging/bridging strategies, SBRT, and evolving LRT techniques.
Systemic therapy landscape: First-line and beyond-first-line immunotherapy and targeted therapy, dual-checkpoint strategies, toxicity management in cirrhotic patients, and late-phase trial updates.
Cholangiocarcinoma focus: Dedicated sessions on diagnosis, staging, surgery, locoregional therapy, and precision systemic treatments.
Multidisciplinary integration: Tumor boards, management of portal hypertension in HCC, and real-world decision-making dilemmas.
Interactive case panels: PVTT, intermediate HCC with combination therapy, oligometastatic disease, and challenging CCA scenarios, encouraging audience participation and voting.
2024
Look Back at ILCA School
Relive the Best Moments
Thanks to the collaborative support of the Korean Association of Liver Cancer, we were thrilled to host the 2024 edition of the ILCA School of Liver Cancer in Seoul.
The ILCA School was a unique learning platform for practitioners and investigators to receive education in an intense, interactive, and multidisciplinary format. This one-day ILCA School covered the latest developments in liver cancer research and treatment, including updates on tumour biology, clinical trial advances, and expert insights on management strategies. Additionally, we helped to enhance your research tools, such as oral presentation and statistical interpretation skills. It was a productive and engaging meeting!
We extend our heartfelt thanks to everyone who attended the 2024 edition.
Grant
The ILCA School of Liver Cancer 2024 was supported by an unrestricted educational grant from Bayer
